ClinicalTrials.gg
CompletedNCT01826214Updated Aug 30, 2016Results posted

Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia

A Phase 2 interventional study of LDE225 in Acute Leukemias, sponsored by Novartis Pharmaceuticals. Completed at 23 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Leukemia, Myeloid, Acute by Novartis — none open to participants now, 3 under way, none of them phase 3. Leukemia, Myeloid, Acute · Novartis.

Enrollment
15th of 36
70 · median 64
Started
2013
with 4 others
Phase 2
12 of 40
none open now
Registered
14th of 40
by date

Among the 40 studies in Leukemia, Myeloid, Acute by Novartis, this one is the 15th largest by enrollment of the 36 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 2, and was the 14th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

None of the 40 studies in Leukemia, Myeloid, Acute by Novartis is open now. The open studies under Leukemia, Myeloid, Acute, anywhere →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies in Leukemia, Myeloid, Acute by Novartis as a file.
02

Study summary

The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.

03

Conditions studied

  • Acute Leukemias

Keywords

  • acute myeloid leukemia
  • AML
  • acute lymphoblastic leukemia
  • ALL
  • leukemia
  • acute
  • LDE225
  • adult patients
  • relapsed/refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have or primary refractory non-M3 acute myeloid leukemia or relapsed or refractory non-T-cell acute lymphoblastic leukemia or untreated acute myeloid leukemia in elderly patients.
  • Performance status of 0, 1 or 2 per WHO classification.
  • Adequate renal and liver function.
  • Adequate blood creatine kinase value (CK \< 1.5ULN)

Exclusion criteria

Exclusion Criteria:

  • stem cell transplantation within the last 4 months and/or active requiring systemic therapy, or autologous stem cell transplantation within the last 4 weeks.
  • Patient for which immediate allogeneic stem cell transplantation is the treatment of choice.
  • Pregnant or nursing (lactating) women.
  • Active CNS leukemic involvement
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    LDE225-400

    Patients who were randomized to Schedule A, and received 400 mg LDE225 twice daily for the first two weeks only and then after two weeks, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.

    Drug: LDE225

  • Experimental
    LDE225-800

    Patients who were randomized to Schedule B, received 800 mg LDE225 once daily until disease progression, toxicity, withdrawal of consent, death, discretion of the investigator or early termination of the study.

    Drug: LDE225

Interventions

  • DrugLDE225

    LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.

06

What researchers measure

Primary outcomes

  1. Rate of Complete Remission (CR)

    Complete Response (CR) was based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CR. A treatment cycle was defined as 4 weeks. The outcome measure for the study is based on standardized response criteria as defined by the International Working Group (IWG) for AML. The IWG was established by a group of investigators interested in the design and conduct of clinical trials in acute myeloid leukemia (AML). The criteria established by this group (a set of recommendations for response assessment) are well established, endorsed by major institutions and Health Authorities, and are widely used in clinical trials. No statistical analysis was planned for this primary outcome.

    Time frame: at screening, every week up to Week 9, every 2 weeks thereafter until CR, every 4 weeks after CR up to 24 months

  2. Complete Remission With Incomplete Blood Count Recovery (CRi)

    The other primary efficacy endpoint was CRi based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CRi. A treatment cycle was defined as 4 weeks. No statistical analysis was planned for this primary outcome.

    Time frame: within 3 days after clearance of blasts from peripheral blood (PB), monthly thereafter until CR or reappearance of blasts in the PB, after CR every other month until discontination up to 24 months

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was the rate of complete remission (CR), complete remission with incomplete blood count recovery (CRi) or partial response (PR) according to IWG criteria. CR, CRi or PR will be assessed through bone marrow biopsy/aspirate and peripheral blood blasts counts.

    Time frame: Every 8 weeks for the first 6 months and every 12 weeks until 53 weeks after the last patient is enrolled or until relapse up to 24 months

  2. Parmacokintics (PK) Parameter: Cmax

    Cmax is the maximum observed plasma concentration after drug administration.The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the pharmacokineticist. Cmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

    Time frame: Week 1 Day 1, Week 9 Day 1

  3. Parmacokintics (PK) Parameter: Tmax

    Tmax is the time to reach Cmax. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. Tmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

    Time frame: Week 1 Day 1,Week 9 Day 1

  4. Parmacokintics (PK) Parameter: AUC0-8h

    AUC0-8h is the area under the concentration-time curve from time zero to 8 hours. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-8h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

    Time frame: Week 1 Day 1,Week 9 Day 1

  5. Parmacokintics (PK) Parameter: AUC0-24h

    AUC0-24 is the area under the concentration-time curve from time zero to 24 hours done only on 800 mg once a day schedule. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-24h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

    Time frame: Week 1 Day 1,Week 9 Day 1

07

Results

Posted May 20, 2016
Limitations and caveats
Only 34 of the 35 patients in the LDE225 800 mg once daily arm received at least dose of study drug were analyzed for safety.

Participant flow

Participant flow — Overall Study
MilestoneLDE225-400LDE225-800
Started3534
Untreated01
Treated3534
Completed00
Not completed3534
Withdrew: Adverse event76
Withdrew: Death31
Withdrew: Lost to follow-up10
Withdrew: Physician decision02
Withdrew: Progressive disease2221
Withdrew: Study terminated by sponsor01
Withdrew: Subject/guardian decision23

Outcome measures

PrimaryRate of Complete Remission (CR)

Complete Response (CR) was based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CR. A treatment cycle was defined as 4 weeks. The outcome measure for the study is based on standardized response criteria as defined by the International Working Group (IWG) for AML. The IWG was established by a group of investigators interested in the design and conduct of clinical trials in acute myeloid leukemia (AML). The criteria established by this group (a set of recommendations for response assessment) are well established, endorsed by major institutions and Health Authorities, and are widely used in clinical trials. No statistical analysis was planned for this primary outcome.

Time frame:
at screening, every week up to Week 9, every 2 weeks thereafter until CR, every 4 weeks after CR up to 24 months
Reported as:
Number · Participants
Rate of Complete Remission (CR)
ParticipantsLDE225-400LDE225-800
Rate of Complete Remission (CR)00
PrimaryComplete Remission With Incomplete Blood Count Recovery (CRi)

The other primary efficacy endpoint was CRi based on the International Working Group (IWG) criteria based on weekly peripheral blood count measurements and bone marrow biopsy/aspiration collection. Efficacy assessments were performed to determine CRi. A treatment cycle was defined as 4 weeks. No statistical analysis was planned for this primary outcome.

Time frame:
within 3 days after clearance of blasts from peripheral blood (PB), monthly thereafter until CR or reappearance of blasts in the PB, after CR every other month until discontination up to 24 months
Reported as:
Number · Participants
Complete Remission With Incomplete Blood Count Recovery (CRi)
ParticipantsLDE225-400LDE225-800
Complete Remission With Incomplete Blood Count Recovery (CRi)10
SecondaryOverall Response Rate (ORR)

ORR was the rate of complete remission (CR), complete remission with incomplete blood count recovery (CRi) or partial response (PR) according to IWG criteria. CR, CRi or PR will be assessed through bone marrow biopsy/aspirate and peripheral blood blasts counts.

Time frame:
Every 8 weeks for the first 6 months and every 12 weeks until 53 weeks after the last patient is enrolled or until relapse up to 24 months
Reported as:
Number · Participants
Overall Response Rate (ORR)
ParticipantsLDE225-400LDE225-800
Overall Response Rate (ORR)10
SecondaryParmacokintics (PK) Parameter: Cmax

Cmax is the maximum observed plasma concentration after drug administration.The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the pharmacokineticist. Cmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

Time frame:
Week 1 Day 1, Week 9 Day 1
Reported as:
Mean · ng/mL
Parmacokintics (PK) Parameter: Cmax
ng/mLLDE225-400LDE225-800
Week 1 Day 1237 ± 158343 ± 275
Week 9 Day 1(n: 7, 7)1640 ± 6121500 ± 874
SecondaryParmacokintics (PK) Parameter: Tmax

Tmax is the time to reach Cmax. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. Tmax was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

Time frame:
Week 1 Day 1,Week 9 Day 1
Reported as:
Median · hr
Parmacokintics (PK) Parameter: Tmax
hrLDE225-400LDE225-800
Week 1 Day 12.13 ± NA2.12 ± NA
Week 9 Day 1 (n: 7, 7)1.88 ± NA2.02 ± NA
SecondaryParmacokintics (PK) Parameter: AUC0-8h

AUC0-8h is the area under the concentration-time curve from time zero to 8 hours. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-8h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

Time frame:
Week 1 Day 1,Week 9 Day 1
Reported as:
Mean · ng*hr/mL
Parmacokintics (PK) Parameter: AUC0-8h
ng*hr/mLLDE225-400LDE225-800
Week 1 Day1988 ± 5421560 ± 1230
Week 9 Day1 (n: 7, 7)9750 ± 28307910 ± 5090
SecondaryParmacokintics (PK) Parameter: AUC0-24h

AUC0-24 is the area under the concentration-time curve from time zero to 24 hours done only on 800 mg once a day schedule. The PK parameters were determined in plasma using non-compartmental methods. A PK sample was excluded from analyses if the patient vomited within the first 4 hours following the last oral dose of study drug. Other PK samples were excluded as deemed appropriate by the Pharmacokineticist. AUC0-24h was derived from the PK concentrations collected at 0, 0.5, 1, 2, 4, 6, 8 and 24 hours post dose on W1D1 and W9D1. The PK concentration at each time point is not an endpoint in the protocol, but these concentrations are used to derive the PK parameters.

Time frame:
Week 1 Day 1,Week 9 Day 1
Reported as:
Mean · ng*hr/mL
Parmacokintics (PK) Parameter: AUC0-24h
ng*hr/mLLDE225-400LDE225-800
Week 1 Day 10 ± 03110 ± 2620
Week 9 Day 1 (n: 7, 6)26500 ± 665024000 ± 11500

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225-400—25/35 (71.4%)35/35 (100%)
LDE225-800—25/34 (73.5%)34/34 (100%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventLDE225-400LDE225-800
FEBRILE NEUTROPENIABlood and lymphatic system disorders9/357/34
PYREXIAGeneral disorders1/354/34
SEPSISInfections and infestations2/354/34
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders4/351/34
PNEUMONIAInfections and infestations3/353/34
ANAEMIABlood and lymphatic system disorders0/352/34
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations2/352/34
EPISTAXISRespiratory, thoracic and mediastinal disorders1/352/34
ASTHENIAGeneral disorders2/351/34
LUNG INFECTIONInfections and infestations2/350/34
Most frequent other events
Showing 10 of 82
Most frequent other events
EventLDE225-400LDE225-800
VOMITINGGastrointestinal disorders7/3512/34
NAUSEAGastrointestinal disorders11/3510/34
FATIGUEGeneral disorders8/3510/34
PYREXIAGeneral disorders7/3510/34
CONSTIPATIONGastrointestinal disorders6/358/34
DIARRHOEAGastrointestinal disorders7/358/34
MYALGIAMusculoskeletal and connective tissue disorders4/358/34
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations8/357/34
MUSCLE SPASMSMusculoskeletal and connective tissue disorders8/355/34
THROMBOCYTOPENIABlood and lymphatic system disorders7/355/34

Baseline characteristics

Full analysis set (FAS): comprised of all patients who were randomized to a study treatment. According to the intent-to-treat principle, patient data were analyzed according to the treatment to which they had been randomized.

Age, Continuous
Age, Continuous(Years)LDE225-400LDE225-800Total
Mean65.3 ± 12.3167.7 ± 11.6566.5 ± 11.96
Sex: Female, Male
Sex: Female, Male(Participants)LDE225-400LDE225-800Total
Female181331
Male172239
08

Study locations

23 sites
  • Duke University Medical Center SC-5
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Prahran, Victoria 3181, Australia
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Wien, 1090, Austria
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Magdeburg, 39120, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Amsterdam, 1081 HV, Netherlands
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3015 CE, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3075 EA, Netherlands
  • Novartis Investigative Site
    Bergen, NO-5021, Norway
  • Novartis Investigative Site
    Trondheim, 7006, Norway
  • Novartis Investigative Site
    Salamanca, Castilla y Leon 37007, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    London, WC1E 6HX, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2013
First posted
Apr 8, 2013
Start
May 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
May 20, 2016
Last update
Aug 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01826214
Responsible party
Sponsor
First posted
Apr 8, 2013
Start date
May 2013
Primary completion
May 2015
Completion
May 2015
Results posted
May 20, 2016
Last update
Aug 30, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion